赛诺菲全景展示生态价值链中国实践

Core Viewpoint - Sanofi showcases its commitment to the Chinese market and patients by presenting its advancements in high-quality manufacturing, supply chain, immunology innovations, and patient health empowerment at the 3rd China International Supply Chain Promotion Expo [1] Group 1: Company Commitment and Achievements - Sanofi has been operating in China for over 40 years, establishing a comprehensive ecological value chain that includes local R&D, manufacturing, and patient services [1] - The year 2023 marks the 30th anniversary of Sanofi's localized manufacturing in China, highlighting its long-term commitment to the market [1] - Sanofi plans to invest €1 billion in a new production base in Beijing by December 2024, focusing on end-to-end localized production capabilities for insulin products to meet the growing demand from diabetes patients in China [1] Group 2: Supply Chain and Manufacturing Innovations - At the expo, Sanofi presented a model demonstrating the entire process of flu vaccine production, from France to local manufacturing in Shenzhen, showcasing its supply chain and manufacturing advantages [2] - The Shenzhen factory represents a significant upgrade from "manufacturing" to "intelligent manufacturing," with all key steps of flu vaccine production being localized [2] - Sanofi employs a comprehensive quality management system that ensures traceability throughout the vaccine storage and transportation process, reinforcing vaccine safety [2]